Closures a sign of Novartis minimizing production in Switzerland

The recently announced site closures by Novartis ($NVS) in Switzerland may be an indication that the country's pharmaceutical industry is being forced to move away from mass production. "High quality products that require a lot of research and development will always be made in Switzerland while finished products will be made elsewhere," said Julius Bär economist Janwillem Acket in Le Temps. Story

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.